A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia

Martin Scharf, Milton Erman, Russell Rosenberg, David Seiden, William Vaughn McCall, David Amato, Thomas C. Wessel

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Study Objectives: Evaluate the efficacy of eszopiclone in primary insomnia. Design/Setting: Randomized, double-blind, placebo-controlled multicenter in outpatient setting with weekly visits. Participants: Two-hundred thirty one men and women aged 65 to 85 years (mean age 72.3 years) with primary insomnia, as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition. Interventions: Eszopiclone 1 mg (n = 72), eszopiclone 2 mg (n = 79), or placebo (n = 80) nightly for 2 weeks. Measurements/Results: Efficacy was assessed using an interactive voice response system. Following the predefined hierarchical testing strategy, the eszopiclone 2-mg group had a significantly shorter sleep latency compared with placebo over the double-blind period (P = .0034). The eszopiclone 2-mg group had significantly longer total sleep time (P = .0003) and eszopiclone 1-mg group had significantly shorter sleep latency (P ≤ .012) compared with placebo. The eszopiclone 1-mg group was not significantly different from placebo on total sleep time or any other secondary efficacy endpoint. Secondary analyses indicated that the eszopiclone 2-mg group had significantly less wake after sleep onset; significantly fewer and shorter in duration daytime naps; and significantly higher ratings of sleep quality and depth, daytime alertness, and sense of physical well-being compared with placebo (P < .05). Eszopiclone was well tolerated. The most frequent treatment-related adverse event was unpleasant taste. Conclusion: Nightly treatment with eszopiclone 1 mg effectively induced sleep, while the 2-mg dose was effective in inducing and maintaining sleep. Eszopiclone was well tolerated in elderly patients with primary insomnia, and the sleep efficacy was accompanied by significantly less napping and significantly higher ratings of daytime alertness, sense of physical well-being, and several quality-of-life parameters at the higher dose.

Original languageEnglish (US)
Pages (from-to)720-727
Number of pages8
JournalSleep
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2005
Externally publishedYes

Fingerprint

Sleep Initiation and Maintenance Disorders
Sleep
Safety
Placebos
Eszopiclone
Diagnostic and Statistical Manual of Mental Disorders
Outpatients
Quality of Life

Keywords

  • Daytime function
  • Elderly
  • Eszopiclone
  • Insomnia
  • Quality of life
  • Sleep disturbance
  • Sleep latency
  • Sleep maintenance
  • WASO

ASJC Scopus subject areas

  • Clinical Neurology
  • Physiology (medical)

Cite this

Scharf, M., Erman, M., Rosenberg, R., Seiden, D., McCall, W. V., Amato, D., & Wessel, T. C. (2005). A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep, 28(6), 720-727. https://doi.org/10.1093/sleep/28.6.720

A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. / Scharf, Martin; Erman, Milton; Rosenberg, Russell; Seiden, David; McCall, William Vaughn; Amato, David; Wessel, Thomas C.

In: Sleep, Vol. 28, No. 6, 01.06.2005, p. 720-727.

Research output: Contribution to journalArticle

Scharf, M, Erman, M, Rosenberg, R, Seiden, D, McCall, WV, Amato, D & Wessel, TC 2005, 'A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia', Sleep, vol. 28, no. 6, pp. 720-727. https://doi.org/10.1093/sleep/28.6.720
Scharf, Martin ; Erman, Milton ; Rosenberg, Russell ; Seiden, David ; McCall, William Vaughn ; Amato, David ; Wessel, Thomas C. / A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. In: Sleep. 2005 ; Vol. 28, No. 6. pp. 720-727.
@article{c375d5c6f8514868bbd6e9c1cac92b19,
title = "A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia",
abstract = "Study Objectives: Evaluate the efficacy of eszopiclone in primary insomnia. Design/Setting: Randomized, double-blind, placebo-controlled multicenter in outpatient setting with weekly visits. Participants: Two-hundred thirty one men and women aged 65 to 85 years (mean age 72.3 years) with primary insomnia, as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition. Interventions: Eszopiclone 1 mg (n = 72), eszopiclone 2 mg (n = 79), or placebo (n = 80) nightly for 2 weeks. Measurements/Results: Efficacy was assessed using an interactive voice response system. Following the predefined hierarchical testing strategy, the eszopiclone 2-mg group had a significantly shorter sleep latency compared with placebo over the double-blind period (P = .0034). The eszopiclone 2-mg group had significantly longer total sleep time (P = .0003) and eszopiclone 1-mg group had significantly shorter sleep latency (P ≤ .012) compared with placebo. The eszopiclone 1-mg group was not significantly different from placebo on total sleep time or any other secondary efficacy endpoint. Secondary analyses indicated that the eszopiclone 2-mg group had significantly less wake after sleep onset; significantly fewer and shorter in duration daytime naps; and significantly higher ratings of sleep quality and depth, daytime alertness, and sense of physical well-being compared with placebo (P < .05). Eszopiclone was well tolerated. The most frequent treatment-related adverse event was unpleasant taste. Conclusion: Nightly treatment with eszopiclone 1 mg effectively induced sleep, while the 2-mg dose was effective in inducing and maintaining sleep. Eszopiclone was well tolerated in elderly patients with primary insomnia, and the sleep efficacy was accompanied by significantly less napping and significantly higher ratings of daytime alertness, sense of physical well-being, and several quality-of-life parameters at the higher dose.",
keywords = "Daytime function, Elderly, Eszopiclone, Insomnia, Quality of life, Sleep disturbance, Sleep latency, Sleep maintenance, WASO",
author = "Martin Scharf and Milton Erman and Russell Rosenberg and David Seiden and McCall, {William Vaughn} and David Amato and Wessel, {Thomas C.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1093/sleep/28.6.720",
language = "English (US)",
volume = "28",
pages = "720--727",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "6",

}

TY - JOUR

T1 - A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia

AU - Scharf, Martin

AU - Erman, Milton

AU - Rosenberg, Russell

AU - Seiden, David

AU - McCall, William Vaughn

AU - Amato, David

AU - Wessel, Thomas C.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Study Objectives: Evaluate the efficacy of eszopiclone in primary insomnia. Design/Setting: Randomized, double-blind, placebo-controlled multicenter in outpatient setting with weekly visits. Participants: Two-hundred thirty one men and women aged 65 to 85 years (mean age 72.3 years) with primary insomnia, as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition. Interventions: Eszopiclone 1 mg (n = 72), eszopiclone 2 mg (n = 79), or placebo (n = 80) nightly for 2 weeks. Measurements/Results: Efficacy was assessed using an interactive voice response system. Following the predefined hierarchical testing strategy, the eszopiclone 2-mg group had a significantly shorter sleep latency compared with placebo over the double-blind period (P = .0034). The eszopiclone 2-mg group had significantly longer total sleep time (P = .0003) and eszopiclone 1-mg group had significantly shorter sleep latency (P ≤ .012) compared with placebo. The eszopiclone 1-mg group was not significantly different from placebo on total sleep time or any other secondary efficacy endpoint. Secondary analyses indicated that the eszopiclone 2-mg group had significantly less wake after sleep onset; significantly fewer and shorter in duration daytime naps; and significantly higher ratings of sleep quality and depth, daytime alertness, and sense of physical well-being compared with placebo (P < .05). Eszopiclone was well tolerated. The most frequent treatment-related adverse event was unpleasant taste. Conclusion: Nightly treatment with eszopiclone 1 mg effectively induced sleep, while the 2-mg dose was effective in inducing and maintaining sleep. Eszopiclone was well tolerated in elderly patients with primary insomnia, and the sleep efficacy was accompanied by significantly less napping and significantly higher ratings of daytime alertness, sense of physical well-being, and several quality-of-life parameters at the higher dose.

AB - Study Objectives: Evaluate the efficacy of eszopiclone in primary insomnia. Design/Setting: Randomized, double-blind, placebo-controlled multicenter in outpatient setting with weekly visits. Participants: Two-hundred thirty one men and women aged 65 to 85 years (mean age 72.3 years) with primary insomnia, as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition. Interventions: Eszopiclone 1 mg (n = 72), eszopiclone 2 mg (n = 79), or placebo (n = 80) nightly for 2 weeks. Measurements/Results: Efficacy was assessed using an interactive voice response system. Following the predefined hierarchical testing strategy, the eszopiclone 2-mg group had a significantly shorter sleep latency compared with placebo over the double-blind period (P = .0034). The eszopiclone 2-mg group had significantly longer total sleep time (P = .0003) and eszopiclone 1-mg group had significantly shorter sleep latency (P ≤ .012) compared with placebo. The eszopiclone 1-mg group was not significantly different from placebo on total sleep time or any other secondary efficacy endpoint. Secondary analyses indicated that the eszopiclone 2-mg group had significantly less wake after sleep onset; significantly fewer and shorter in duration daytime naps; and significantly higher ratings of sleep quality and depth, daytime alertness, and sense of physical well-being compared with placebo (P < .05). Eszopiclone was well tolerated. The most frequent treatment-related adverse event was unpleasant taste. Conclusion: Nightly treatment with eszopiclone 1 mg effectively induced sleep, while the 2-mg dose was effective in inducing and maintaining sleep. Eszopiclone was well tolerated in elderly patients with primary insomnia, and the sleep efficacy was accompanied by significantly less napping and significantly higher ratings of daytime alertness, sense of physical well-being, and several quality-of-life parameters at the higher dose.

KW - Daytime function

KW - Elderly

KW - Eszopiclone

KW - Insomnia

KW - Quality of life

KW - Sleep disturbance

KW - Sleep latency

KW - Sleep maintenance

KW - WASO

UR - http://www.scopus.com/inward/record.url?scp=20444417371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444417371&partnerID=8YFLogxK

U2 - 10.1093/sleep/28.6.720

DO - 10.1093/sleep/28.6.720

M3 - Article

VL - 28

SP - 720

EP - 727

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 6

ER -